Trials / Completed
CompletedNCT02906579
A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension
An Open-label, Phase 2a Trial to Evaluate the Effect of Escalating Doses of IW-1973 on Tolerability, Endothelial Function, and Hemodynamics in Patients With Stable Type 2 Diabetes and Hypertension
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Cyclerion Therapeutics · Industry
- Sex
- All
- Age
- 30 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the impact of escalating doses of IW-1973 on endothelial function \[using EndoPAT to measure fingertip small vessel pulse volume\], blood pressure (BP), and heart rate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Matching Placebo | |
| DRUG | IW-1973 |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2017-03-17
- Completion
- 2017-03-17
- First posted
- 2016-09-20
- Last updated
- 2020-04-16
- Results posted
- 2020-04-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02906579. Inclusion in this directory is not an endorsement.